Drug Trial Radar · NCT04657068
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
542
Planned (sponsor's estimate)
Start
Jan 27, 2021
Primary completion
Jan 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- Artios Pharma LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 8, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan * Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan
Conditions
- Advanced Cancer
- Metastatic Cancer
- Ovarian Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer
- Endometrial Cancer
- Metastatic Colorectal Cancer
- Pancreatic Ductal Adenocarcinoma
- Acinar Cell Carcinoma
Interventions
ART0380Drug
Participants will receive ART0380 by mouth either intermittently (either once daily 3 days on, 4 days off; days 2-4 and 9-11;or days 1-3 and 8-10) or continuously (once daily each day) in 21 day cycles.
GemcitabineDrug
Gemcitabine will be administered on Days 1 and 8 of a 21-day cycle.
IrinotecanDrug
Irinotecan will be administered as a 90-minute infusion on Days 1 and 8 of a 21 day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Maximum tolerated dose (MTD) by the number of participants with dose limiting toxicities (DLTs) from ART0380 monotherapy and in combination with gemcitabine or irinotecanTime frame: From Cycle 0 Day -2 to Cycle 1 Day 21. Each cycle is 21 days.
- Parts B1/B3/B4: Number of participants with adverse events following administration of ART0380 monotherapy and/or in combination with irinotecan at RP2Ds.Time frame: From Cycle 1 Day 1 until up to 30 days after the last dose of ART0380. Each cycle is 21 days.
- Part B2: Progression free survival by RECIST 1.1 in participants receiving ART0380 in combination with gemcitabine or gemcitabine aloneTime frame: Every 6 weeks from Cycle 1 Day 1 for 18 weeks, then every 9 weeks up to approximately 24 months. Each cycle is 21 days.
- Parts B5/B6: Object Response Rate (ORR) based on RECIST 1.1 to access anti-tumor activity of ART0380 in combination with irinotecan in each cohort.Time frame: Every 6 weeks from Cycle 1 Day 1, until disease progression or death or start of a new anti-cancer therapy, up to 2 years. Each Cycle is 21 days.
Locations
88 sites in 4 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Mayo Clinic (Arizona)
Scottsdale, Arizona · Recruiting
University of Arkansas - Winthrop P. Rockefeller Cancer Institute
Little Rock, Arkansas · Completed
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
Sansum Clinic
Santa Barbara, California · Active not recruiting
Providence Medical Foundation
Santa Rosa, California · Recruiting
Rocky Mountain Cancer Center
Denver, Colorado · Active not recruiting
Sarah Cannon Research Institute at HealthONE
Denver, Colorado · Recruiting
The Sidney Kimmel Comprehensive Cancer Center (Johns Hopkins)
Washington D.C., District of Columbia · Recruiting
Florida Cancer Specialists
Fort Myers, Florida · Recruiting
Mayo Clinic (Florida)
Jacksonville, Florida · Recruiting
Cancer Specialists of North Florida
Jacksonville, Florida · Active not recruiting
Florida Cancer Specialists
Orlando, Florida · Completed
Florida Cancer Specialists
Sarasota, Florida · Active not recruiting
Florida Cancer Specialists
West Palm Beach, Florida · Active not recruiting
Hope and Healing Cancer Services
Hinsdale, Illinois · Active not recruiting
Community Health Network
Indianapolis, Indiana · Recruiting
Our Lady of the Lake
Baton Rouge, Louisiana · Completed
Maryland Oncology Hematology - Primary
Columbia, Maryland · Active not recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Minnesota Oncology Hematology
Maple Grove, Minnesota · Recruiting
Mayo Clinic (Minnesota)
Rochester, Minnesota · Recruiting
Washington University
St Louis, Missouri · Recruiting
Hematology Oncology Associates of Central New York
East Syracuse, New York · Recruiting
Northwell Health Cancer Institute
Lake Success, New York · Recruiting
Memorial Sloan-Kettering Cancer Center
New York, New York · Recruiting
Oncology Hematology Care Primary
Cincinnati, Ohio · Recruiting
Taylor Cancer Research Center
Maumee, Ohio · Recruiting
Stephenson Cancer Center
Oklahoma City, Oklahoma · Recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
University of Pennsylvania / Abramson Cancer Center
Philadelphia, Pennsylvania · Recruiting
Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization
Philadelphia, Pennsylvania · Recruiting
Tennessee Oncology, PLLC
Chattanooga, Tennessee · Completed
Baptist Cancer Center
Memphis, Tennessee · Completed
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Vanderbilt Medical Center
Nashville, Tennessee · Recruiting
Texas Oncology - Central/South Texas
Austin, Texas · Active not recruiting
Mary Crowley Cancer Research
Dallas, Texas · Recruiting
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas · Active not recruiting
University of Texas Southwestern
Dallas, Texas · Recruiting
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.